Literature DB >> 9276762

Rifamycins inhibit human neutrophil functions: new derivatives with potential antiinflammatory activity.

S Spisani1, S Traniello, C Martuccio, O Rizzuti, L Cellai.   

Abstract

In our study we investigated the effect of rifamycin SV, rifamycin B, rifampicin and five semisynthetic derivatives on human neutrophil functions such as locomotion, superoxide production and degranulation stimulated by specific agonists. All compounds were tested at concentrations ranging from 10(-9) to 10(-5) M. Among the newly synthesized compounds the most active we found to be the derivatives carrying an acidic substituent at C3: these significantly lowered the superoxide generation induced by PMA throughout the entire concentration range, whereas rifamycin SV, rifamycin B and rifampicin were effective only at the highest concentrations. Moreover, chemotactic movement was significantly attenuated by derivative R4, rifamycin B and rifamycin SV at high doses; granule enzyme release was unaffected by all compounds.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9276762     DOI: 10.1023/a:1027314419843

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  17 in total

1.  CD16 and CR3 receptors distinguish between the two mechanisms of tumour cytotoxicity in neutrophils.

Authors:  R Gavioli; S Spisani; A L Giuliani; E Cosulich; A Risso; S Traniello
Journal:  Br J Haematol       Date:  1991-10       Impact factor: 6.998

2.  Rifampin therapy in rheumatoid arthritis.

Authors:  S E Gabriel; D L Conn; H Luthra
Journal:  J Rheumatol       Date:  1990-02       Impact factor: 4.666

3.  In vivo and in vitro suppression of humoral and cellular immunological response by rifampicin.

Authors:  E Păunescu
Journal:  Nature       Date:  1970-12-19       Impact factor: 49.962

4.  Prevention of appearance of radiological lesions in early rheumatoid arthritis: a randomized, single-blind study comparing intra-articular rifamycin with auranofin.

Authors:  I Caruso; S Santandrea; P Sarzi Puttini; F Montrone; L Boccassini; V Azzolini; M Cazzola; D Dell'Acqua
Journal:  J Int Med Res       Date:  1992-02       Impact factor: 1.671

5.  Hypolipidemic activity of rifamycin derivatives.

Authors:  P Traxler; W Kump; K Mueller; W Tosch
Journal:  J Med Chem       Date:  1990-02       Impact factor: 7.446

6.  The effect of rifamycin SV on neutrophil functions in patients with rheumatoid arthritis.

Authors:  S Spisani; L Dovigo; G Corazza; R Carletti; S Traniello
Journal:  Scand J Rheumatol       Date:  1982       Impact factor: 3.641

7.  Rifamycin SV in local treatment of synovitis--a clinical, arthroscopic and pharmacologic evaluation.

Authors:  S Lindblad; E Hedfors; A S Malmborg
Journal:  J Rheumatol       Date:  1985-10       Impact factor: 4.666

8.  Rifamycin SV versus triamcinolone in local treatment of rheumatoid synovitis.

Authors:  A Marchesoni; L Sinigaglia; R Ranza; M Varenna; N Battafarano; S Tosi
Journal:  Scand J Rheumatol       Date:  1993       Impact factor: 3.641

9.  Antiinflammatory effects of NADPH oxidase inhibitors.

Authors:  R Miesel; D Sanocka; M Kurpisz; H Kröger
Journal:  Inflammation       Date:  1995-06       Impact factor: 4.092

10.  Leukocyte locomotion and chemotaxis. New methods for evaluation, and demonstration of a cell-derived chemotactic factor.

Authors:  S H Zigmond; J G Hirsch
Journal:  J Exp Med       Date:  1973-02-01       Impact factor: 14.307

View more
  4 in total

1.  Interaction of rifalazil with oxidant-generating systems of human polymorphonuclear neutrophils.

Authors:  M T Labro; V Ollivier; C Babin-Chevaye
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

2.  3-(Carboxyalkylthio) rifamycin S and SV derivatives inhibit human neutrophil functions.

Authors:  S Spisani; S Traniello; A M Onori; O Rizzuti; C Martuccio; L Cellai
Journal:  Inflammation       Date:  1998-10       Impact factor: 4.092

3.  Successful combined antibiotic therapy with oral clindamycin and oral rifampicin for pyoderma gangrenosum in patient with PASH syndrome.

Authors:  Marie Lamiaux; Fadia Dabouz; Maud Wantz; Damien Lebas; Audrey Lasek; Domitille Courivaud; Philippe Modiano
Journal:  JAAD Case Rep       Date:  2017-12-18

4.  Rifamycin SV-MMX® for treatment of travellers' diarrhea: equally effective as ciprofloxacin and not associated with the acquisition of multi-drug resistant bacteria.

Authors:  Robert Steffen; Zhi-Dong Jiang; Mónica L Gracias Garcia; Prithi Araujo; Michael Stiess; Tanju Nacak; Roland Greinwald; Herbert L DuPont
Journal:  J Travel Med       Date:  2018-01-01       Impact factor: 8.490

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.